No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

USA: In a significant advancement for the treatment of severe alopecia areata (AA), long-term data from two phase III ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

Lilly and Incyte's already-marketed JAK inhibitor Olumiant (baricitinib) is currently in the lead among drugs for alopecia areata, with a filing due in the second half of this year after two ...

Patients were in their early 50s on average, and some 80% were women. Nearly all were white (most participants were from ...

Maryanne Senna, MD, assistant professor of dermatology at Harvard Medical School, discusses the results of the case and the impact JAK inhibitors have had on the treatment of alopecia areata ...

Adding narrowband ultraviolet B (UVB) phototherapy to oral treatment with ritlecitinib (Litfulo) enhanced repigmentation in ...

GCA is an autoimmune condition, predominantly affecting individuals over 50, with the highest incidence between 70 and 80 ...

we have seen two oral [Janus kinase (JAK)] inhibitors be approved for alopecia areata, and these medicines are really pathogenesis-directed treatment, so they are very effective for many patients ...

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...